Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model

Neuroendocrinology Letters

Volumn 30, Issue 1, 2009, Pages 144-152

  Bujalska, Magdalena ^a   Makulska Nowak, Helena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Bradykinin; Diabetes; Hyperalgesia; Neuropathic pain; Nitric oxide inhibitors; Streptozotocin; Vincristine

Indexed keywords

7 NITROINDAZOLE; BRADYKININ; ICATIBANT; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE; N6 (1 IMINOETHYL)LYSINE; NEURONAL NITRIC OXIDE SYNTHASE; STREPTOZOCIN; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERALGESIA; LOW DRUG DOSE; MALE; MECHANICAL STIMULATION; NONHUMAN; PAIN THRESHOLD; RAT;

ANIMALS; BRADYKININ; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HYPERALGESIA; HYPOGLYCEMIC AGENTS; INDAZOLES; LYSINE; MALE; NITRIC OXIDE SYNTHASE; NITROARGININE; PAIN MEASUREMENT; RATS; RATS, WISTAR; RECEPTORS, BRADYKININ; STREPTOZOCIN; TETRAHYDROISOQUINOLINES; VINCRISTINE;

EID: 65349182964     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aley KO, Levine JD (2002). Different peripheral mechanisms mediate enhanced nociception in metabolic/toxic and traumatic painful peripheral neuropathies in the rat. Neuroscience. 111: 389-397.
2. Aley KO, Reichling DB, Levine JD (1996). Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 73: 259-265.
3. Bauer MB, Simmons ML, Murphy S, Gebhart GF (1993). Bradykinin and capsaicin stimulate cyclic GMP production in cultured rat dorsal root ganglion neurons via a nitrosyl intermediate. J Neurosci Res. 36: 280-289.
4. Bujalska M, Tatarkiewicz J, de Cordé A, Gumułka SW (2008a). Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats. Pharmacology. 81: 151-157.
5. Bujalska M, Gumułka SW (2008b). Effect of selenium compound (selol) on the opioid activity in vincristine induced hyperalgesia. Neuro Endocrinol Lett. 29: 552-557.
6. Bujalska M, Tatarkiewicz J, Gumułka SW (2008). Effect of bradykinin receptor antagonists on vincristine- and streptozotocin-induced hyperalgesia in a rat model of chemotherapy-induced and diabetic neuropathy. Pharmacology. 81: 158-163.
7. Calixto JB, Cabrini DA, Ferreira J, Campos MM (2000). Kinins in pain and inflammation. Pain. 87: 1-5.
8. Cameron NE, Jack AM, Cotter MA (2001). Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med. 31: 125-135.
9. Campos MM, Ongali B, Thibault G, Neugebauer W, Couture R (2005). Autoradiographic distribution and alterations of kinin B(2) receptors in the brain and spinal cord of streptozotocin-diabetic rats. Synapse. 58: 184-192.
10. Cellek S (2004). Point of NO return for nitrergic nerves in diabetes: a new insight into diabetic complications. Curr Pharm Des. 10: 3683-3695.
11. Cellek S, Anderson PN, Foxwell NA (2005). Nitrergic neurodegeneration in cerebral arteries of streptozotocin-induced diabetic rats: a new insight into diabetic stroke. Diabetes. 54: 212-219.
12. Cellek S, Qu, W, Schmidt AM, Moncada S (2004). Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia. 47: 331-339.
13. Dray A, Perkins M (1993). Bradykinin and inflammatory pain. Trends Neurosci. 16: 99-104.
14. Fox A, Eastwood C, Gentry C, Manning D, Urban L (1999). Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain. 81: 307-316.
15. Gabra BH, Benrezzak O, Pheng LH, Duta D, Daull P, Sirois P, Nantel F, Battistini B (2005). Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced Wistar versus spontaneous gene-prone BB/ Worchester rats: efficacy of a selective bradykinin B1 receptor antagonist. J Neuropathol Exp Neurol. 64: 782-790.
16. 1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy. Biol Chem. 387: 127-143.
17. Gabra BH, Merino VF, Bader M, Pesquero JB, Sirois P (2005). Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice. Regul Pept. 127: 245-248.
18. Gabra BH, Sirois P (2003). Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides. 24: 1131-1139.
19. Gabra BH, Sirois P (2004). Pathways for the bradykinin B1 receptor-mediated diabetic hyperalgesia in mice. Inflamm Res. 53: 653-657.
20. Gabra BH, Sirois P (2005). Hyperalgesia in non-obese diabetic (NOD) mice: a role for the inducible bradykinin B1 receptor. Eur J Pharmacol. 514: 61-67.
21. Holthusen H (1997). Involvement of the NO/cyclic GMP pathway in bradykinin-evoked pain from veins in humans. Pain. 69: 87-92.
22. Joseph EK, Levine JD (2003). Sexual dimorphism in the contribution of protein kinase C isoforms to nociception in the streptozotocin diabetic rat. Neuroscience. 120: 907-913.
23. Kamei J, Tamura N, Saitoh A (2005). Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain. 117: 112-120.
24. Kelly DC, Asghar AU, Marr CG, McQueen DS (2001). Nitric oxide modulates articular sensory discharge and responsiveness to bradykinin in normal and arthritic rats in vivo. Neuroreport. 12: 121-125.
25. Kindgen-Milles D, Arndt JO: Nitric oxide as a chemical link in the generation of pain from veins in humans. Pain 1996; 64: 139-142.
26. Maes M, Mihaylova I, Kubera M, Bosmans E (2007). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett. 28: 463-469.
27. Millan MJ: The induction of pain: an integrative review (1999). Prog Neurobiol. 57: 1-164.
28. Moalem G, Tracey DJ (2006). Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 51: 240-264.
29. Nakamura A, Fujita M, Shiomi H (1996). Involvement of endogenous nitric oxide in the mechanism of bradykinin-induced peripheral hyperalgesia. Br J Pharmacol. 117: 407-412.
30. Nakhoda A, Wong HA (1979). The induction of diabetes in rats by intramuscular administration of streptozotocin. Experientia 35, Birkhäuser Verlag, Basel (Schweiz). 35: 1679-1680.
31. Palmer RM, Ferrige AG, Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327: 524-526.
32. 1 receptors. Proc Natl Acad Sci U S A. 97: 8140-8145.
33. Randall LO, Selitto JJ (1957). A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 111: 409-419.
34. Tallarida RJ, Murray RB: Manual of Pharmacologic Calculation with Computer Programs (1986), ed 2, New York: Springer, 113-117.
35. Teixeira MM, Williams TJ, Hellewell PG (1993). Role of prostaglandins and nitric oxide in acute inflammatory reactions in guinea-pig skin. Br J Pharmacol. 110: 1515-1521.
36. Timar-Peregrin A, Guy RG (2001). Recovery of microvascular responses during streptozotocin-induced diabetes. Eur J Pharmacol. 414: 63-70.
37. Wang H, Ehnert C, Brenner GJ, Woolf CJ (2006). Bradykinin and peripheral sensitization. Biol Chem. 387: 11-14.